Early Access — free while we kick the tires
EdgarHawk

PASSERI DANIEL R

CHIEF EXECUTIVE OFFICER

Director Officer
1 filing analyzed · 1 company · Latest 2024-12-18

Companies

Company Buys Sells Direction
Cue Biopharma, Inc. CUE 1 0 Net buying

Activity

December 2024
2024-12-18 Cue Biopharma, Inc. CUE
high
Buy
30,000 shares
$30,900
Significance 7/10

CUE CEO Daniel Passeri bought 30,000 shares at $1.03 on 2024-12-16; holds 164,578 shares post-transaction despite stock -65.5% from 52-week high.

CEO Daniel Passeri purchased 30,000 shares at $1.03, increasing his holdings to 164,578 shares (+22.3% expansion). The purchase occurred at a steep discount: the current price of $32.10 is -65.5% from the 52-week high of $93.00, and the stock is up +89.4% over the prior 90 days from its lows. Passeri's prior buy at CUE on 2023-08-14 exhibited strong 90-day post-purchase returns (+2323.1%), demonstrating a historical pattern of well-timed entry points at this ticker. The company reported quarterly revenue of $3,336,000.00 with net income of $-8,660,000.00, indicating ongoing losses, though annual revenue growth was +340.9% year-over-year. The combination of a large discretionary accumulation at depressed absolute prices, paired with the insider's demonstrated track record of well-timed purchases at CUE and a company in hypergrowth mode despite current unprofitability, merits investor attention to the conviction signal and underlying business trajectory.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access